A recent update of pharmacogenomics in drug-induced severe skin reactions.

Published

Journal Article (Review)

In some adverse drug reactions (ADRs), genetic predisposition plays a significant role in pathogenesis, and the skin is the most frequently reported target. These severe cutaneous ADRs include bullous fixed drug eruptions (FDE), acute generalized exanthematous pustulosis (AGEP), drug-induced hypersensitivity syndrome (HSS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). The putative contribution of individual effector cells in drug hypersensitivity is briefly mentioned. To trigger these drug hypersensitivities, certain class I HLA alleles (e.g., HLA-A and HLA-B alleles) and certain class II HLA alleles (e.g., HLA-DR alleles) have been recently found to be the genetic determinants. One of the best characterized examples mentioned in this article is HLA-B*1502 to determine the incidence of carbamazepine-induced SJS. How drugs are processed and presented by these HLA alleles to activate immune responses has been explained by several hypotheses. Further implication of pharmagenomic findings to prevent drug-induced severe skin reactions can be achieved by pre-screening putative risk HLA alleles before using drugs.

Full Text

Duke Authors

Cited Authors

  • Wei, C-Y; Ko, T-M; Shen, C-Y; Chen, Y-T

Published Date

  • 2012

Published In

Volume / Issue

  • 27 / 1

Start / End Page

  • 132 - 141

PubMed ID

  • 22041139

Pubmed Central ID

  • 22041139

Electronic International Standard Serial Number (EISSN)

  • 1880-0920

Language

  • eng

Conference Location

  • England